What is the impact of the addition of oxaliplatin to 5-fluorouracil-based preoperative chemoradiation in rectal cancer?

Current Colorectal Cancer Reports

Volumn 7, Issue 1, 2011, Pages 1-4

  Glynne Jones, Robert ^b   Sebag Montefiore, David ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMORADIOTHERAPY; DIARRHEA; HUMAN; PATIENT COMPLIANCE; PREOPERATIVE TREATMENT; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECTUM SURGERY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79952706589     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-010-0071-0     Document Type: Article

References (9)

1. Gerard JP, Conroy T, Bonnetain F, et al.: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625. (Pubitemid 46630960)
2. Bosset JF, Collette L, Calais G, et al.: Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123. (Pubitemid 44394918)
3. Sauer R, Becker H, Hohenberger W, et al. for the German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
4. Quirke P, Steele R, Monson J, et al.; MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI Colorectal Cancer Study Group: Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009, 373(9666):821-828.
5. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al.: Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomized trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004, 72:15-24. (Pubitemid 38952855)
6. Bosset JF, Calais G, Mineur L, et al.: Enhanced tumoricidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results of EORTC 22921. J Clin Oncol 2005, 23:5620-5627.
7. Methy N, Bedenne L, Conroy T, et al.: Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol 2010, 21(3):518-524.
8. Aschele C, Pinto C, Rosati G, et al.: Preoperative (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer; pathologic response analysis of the Studio Terapia Adjuvante Retto (STAR)-01 randomized phase III trial [abstract CRA 4008]. J Clin Oncol 2009, 27(18S):804s.
9. Glynne-Jones R, Anyemene N: Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer? Int J Radiat Oncol Biol Phys 2006, 66(2):319-320.